Trial Profile
Bradykinin B2 Receptor-antagonist Anatibant In Neurotrauma (BRAIN)
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2007
Price :
$35
*
At a glance
- Drugs Anatibant (Primary)
- Indications Chronic brain damage
- Focus Therapeutic Use
- Acronyms BRAIN
- Sponsors Xytis
- 11 Jan 2007 New trial record.